On-demand webinar
Discover how a roadmap based on evidence, not hope, supports stronger business and investment decisions.
Regulatory uncertainty isn’t just a compliance issue. It’s a business risk that threatens funding, timelines and market success
The technical development of innovative medical devices is already demanding.
But for many start-ups, not the tech is the challenge, it is the regulation that is the biggest unknown often causing business risks that can easily be avoided.
Technology-driven MedTech start-ups operate in highly regulated markets while facing pressure from investors, high commercialisation expectations, and limited internal regulatory resources.
Incorrect assumptions on regulation don’t just increase the business risk profile, they directly impact funding milestones, company valuation, and commercial success.
What regulatory uncertainty really costs
- Weak commercialisation
- Missed investor commitments and higher investor pressure
- Delayed market access
- Costly rework
- And growing pressure on already limited teams
Where MedTech start-ups get stuck
- The regulatory roadmap is not developed with business needs in mind
- Complex regulatory requirements lead to decision paralysis
- Available communication offers with Notified Bodies that offer clarity are not utilised
- Limited regulatory and testing expertise in early development phases
- Uncertainty about timelines, planning reliability, and regulatory readiness
- Wrong regulatory assumptions cause project delays, rework, and loss of momentum
TÜV SÜD helps MedTech start-ups turn regulatory business risks into a more predictable and manageable pathway.
Insights from start-up: Bilihome
Insights from start-up: Bilihome
In this video, Bilihome shares how early engagement with TÜV SÜD helped it address regulatory business risks at an early stage. Bilihome is a Dutch start-up with a wearable phototherapy solution for jaundice.
Insights from start-up: Microsure
Insights from start-up: Microsure
In this video, Microsure shares how early engagement with TÜV SÜD helped it address regulatory business risks at an early stage. Microsure is a Dutch start-up with a microsurgical robot.
How TÜV SÜD creates regulatory clarity to enable start-ups get unstuck
TÜV SÜD provides clarity to MedTech start-ups with a close, customer-focused approach that helps reduce uncertainty in the early phases.
Early and simple orientation
instead of information overload to de-risk the regulatory strategy
Clear communication and transparency
on expectations and common regulatory pitfalls
Early involvement
of testing laboratories and Notified Bodies to identify risks upfront
What we offer: Start-up dialogues to reduce regulatory business risk
TÜV SÜD offers early engagement and close communication through structured dialogues, enabling start-ups avoid uncertainty and late-stage surprises.
1. Regulatory and Clinical Roadmap Dialogue - Clarity on timelines, costs and deliverables
Early involvement of a Notified Body and testing experts gives start-ups a reality check on timelines, feasibility and potential pitfalls, reducing regulatory business risk before decisions are fixed. For investors, it signals that risk is being actively managed and that there is alignment between the start-up and TÜV SÜD on timelines, testing activities and certification steps.
2. Intended Purpose and Risk Class Dialogue - Verification of product decisions
Aligning intended purpose, risk classification, and commercial claims early is one of the most underestimated challenges in development. Discussing these with a Notified Body before the scope is locked turns regulatory alignment into a commercial asset and gives investors confidence that commercialisation is built on solid ground.
3. Regulatory Maturity Dialogue - Development of regulatory expertise and processes
For start-ups without a CE certificate, ISO 13485 certification with a limited scope or early third-party testing of product artefacts can provide tangible, regulator-recognised evidence of regulatory maturity. This gives investors confidence that business risk is being actively reduced without waiting for formal product certification.
4. Choosing a Lean Notified Body Dialogue - Choosing the right long-term service provider for flexibility
Choosing a Notified Body is a long-term decision that can directly affect speed, scalability and commercial success. In this dialogue, we discuss how TÜV SÜD's service portfolio aligns with your commercial ambitions across the full product lifecycle, including change handling and lifecycle support for software-driven and medical device software products.
Expert insights on how to reduce regulatory business risks
On-demand webinar
Explore how intended purpose and classification shape regulatory requirements, commercial opportunities and long-term product strategy.
Live Webinar | 12 November 2026 | 11 AM - 12 PM (CEST)
Understanding change-related regulatory considerations for medical device software after certification.
White paper | Leaving the regulatory ivory tower
This white paper explains how early Notified Body dialogues can enable start-ups and investors identify regulatory business risks earlier, build a clearer view of regulatory maturity and make better-informed decisions on the path to CE certification and beyond.
Why TÜV SÜD? Reduced regulatory risk. Reliable business outcomes.
TÜV SÜD can aid MedTech start-ups long before the formal certification process begins. Our all-stage dialogues, designed for start-up needs, help identify regulatory business risk well before they appear and their mitigation is easy.
Execution certainty
Execution certainty from day one through reliable timelines, cost transparency and structured project execution based on clear roadmaps and a single accountable point of contact.
Investor confidence
Higher confidence with investors enabled by credible testing and trusted evidence
Robust regulatory foundations
Robust regulatory foundations built on deep regulatory, product and technology expertise, reducing assumptions and late-stage surprises
Optimised market access
More secure and planned market access through early risk identification and proactive, pragmatic alignment with relevant regulatory stakeholders.
Scalable growth readiness
Sustained regulatory confidence and scalable growth readiness driven by approachable, customer-centric interaction, timely and transparent communication, global applicability (EU & US), and a reputation trusted by investors — not just certification.
Start a dialogue
Disclaimer
TÜV SÜD's certification and testing services are independent of each other and do not impact one another. Our certification services are delivered by TÜV SÜD's recognised Certification Bodies, while our testing services are conducted through TÜV SÜD Testing Labs.